Skip to content
Clinical Trials – home
Recruiting

Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of breast cancer known as hormone-positive breast cancer. This type of cancer grows in response to hormones like estrogen. The study is comparing two different substances used in imaging tests called PET scans, which help doctors see how the cancer is behaving in the body. The two substances being compared are called 18F-FDG and 68Ga-FAPI-46. These substances are injected into the body and help highlight cancer cells during the scan.

The purpose of this study is to find out which of these two substances is better at detecting hormone-positive breast cancer. Participants in the study will receive both substances at different times, and their PET scan results will be compared. This will help researchers understand how well each substance works in identifying cancerous areas that might not be visible with the other substance.

The study will involve a series of PET scans using both 18F-FDG and 68Ga-FAPI-46. The researchers will look at how many cancerous areas are detected by each substance and whether there are any differences in the results. This information will help in planning future studies and improving the way hormone-positive breast cancer is diagnosed and monitored. The study is expected to continue until the end of 2027.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, the patient will undergo an initial assessment to confirm eligibility. This includes verifying the diagnosis of hormone-positive breast cancer and ensuring the patient meets all inclusion criteria.

  2. Step 2

    Consent and preparation

    The patient will provide written informed consent to participate in the study. This step ensures that the patient understands the study procedures and agrees to participate.

  3. Step 3

    First imaging session

    The patient will receive an injection of 18F-FDG, a radioactive tracer used in PET scans. The injection is administered as a solution for injection. The patient will then undergo a PET/CT or PET/MRI scan to assess the presence of cancer lesions.

  4. Step 4

    Second imaging session

    The patient will receive an injection of 68Ga-FAPI-46, another radioactive tracer. This tracer is also administered as a solution for injection. A second PET scan will be performed to compare the detection of cancer lesions with the first imaging session.

  5. Step 5

    Data analysis

    The results from both imaging sessions will be analyzed to determine the number of lesions detected by each tracer. The primary focus is on identifying discordant pairs, where lesions are detected by one tracer but not the other.

  6. Step 6

    Follow-up

    The patient may be asked to return for follow-up assessments to monitor any changes in their condition and to gather additional data for the study.

Who can join the trial?

8 criteria

  • Must be a female patient.
  • Must have a confirmed diagnosis of ER+ breast cancer. This means the cancer cells have receptors for the hormone estrogen, which can help the cancer grow.
  • Must have one of the following conditions:
    • Locally advanced breast cancer: This means the primary tumor is larger than 5 cm, or there are cancer cells in the lymph nodes under the arm.
    • Recurrent breast cancer: This means the cancer has come back after treatment.
    • Metastatic breast cancer: This means the cancer has spread to other parts of the body.
    • Must be undergoing a specific type of imaging test called 18F-FDG PET/CT or 18F-FDG PET/MRI for staging. These are special scans that help doctors see how far the cancer has spread.
    • Must be willing and able to participate in the study procedures.
    • Must have given written consent to participate in the study, meaning they have agreed in writing after being informed about the study.

Who cannot join the trial?

3 criteria

  • Patients who do not have hormone-positive breast cancer cannot participate. This type of breast cancer grows in response to hormones like estrogen.
  • Only female patients are eligible for this study. Male patients cannot participate.
  • Patients who are considered part of a vulnerable population are not eligible. This term refers to groups of people who may have a higher risk of harm or exploitation in research studies.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • 18F-FDG

    is a type of imaging agent used in PET scans. It helps doctors see how tissues and organs are functioning. In this study, it is used to detect cancer cells in patients with ER-positive breast cancer by highlighting areas of high glucose metabolism, which is common in cancer cells.

  • 68Ga-FAPI-46

    is another imaging agent used in PET scans. It targets a specific protein found in cancer cells, making it useful for identifying tumors. In this study, it is being compared to 18F-FDG to see which is more effective in detecting ER-positive breast cancer.

What is already known about the treatment

  • 18F-FDG

    This medication is administered as an injection for use in PET scans, a type of imaging test. It is widely used in medical practice and literature for detecting cancer, including hormone-positive breast cancer. The main therapeutic indication is to help visualize cancerous tissues by highlighting areas of high glucose metabolism, which is common in cancer cells. At the molecular level, 18F-FDG mimics glucose and is taken up by cells, allowing for imaging of metabolic activity. It is classified as a radiopharmaceutical used in diagnostic imaging.

  • 68Ga-FAPI-46

    This medication is also administered via injection for PET imaging. It is currently being studied in clinical trials and is not yet widely established in medical literature. The primary therapeutic indication is to improve the detection of hormone-positive breast cancer by targeting fibroblast activation protein, which is often overexpressed in cancerous tissues. At the molecular level, 68Ga-FAPI-46 binds to this protein, allowing for enhanced imaging of tumors. It is classified as a radiopharmaceutical agent used in diagnostic imaging.

Investigated diseases

Hormone-positive breast cancer – This type of breast cancer is characterized by the presence of receptors for hormones like estrogen or progesterone on the surface of the cancer cells. These receptors allow the cancer cells to grow in response to these hormones. The disease typically progresses as the cancer cells multiply and form a tumor, which can potentially spread to other parts of the body. The growth rate and spread of the cancer can vary, with some cases progressing slowly while others may advance more rapidly. Hormone-positive breast cancer is often detected through imaging tests and may present with symptoms such as a lump in the breast or changes in breast shape. Understanding the hormone receptor status is crucial for determining the appropriate management of the disease.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IITrial ID2023-508066-15-01Estimated enrolment20 patientsSponsorUniversity Hospital Maastricht

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.